H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on January 5 and set a price target of $45.00. The company's shares closed last Tuesday at $6.00, close to its 52-week low of $5.70. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -11.3% and a 25.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics. Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.94.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-actinium-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Déc 2022 à Jan 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2022 à Jan 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals